An immuno-oncology targeting panel accurately characterized tumor-resident immune cells and located pathologically and clinically relevant tumor microenvironment features. Cancer development and ...

IDE892 was discovered through IDEAYA's iterative physics-based ligand design and optimization platform, and is a highly potent and selective MTA-cooperative PRMT5 inhibitor with best-in-class ...